2019 Documentation Packaging 
European Pharmaceutical Review
APRIL 8, 2025
Given that multiple work packages may often start or end together, or else take longer than others ( Figure 1 ), the introduction of new PAT requires assessment and planning by multiple departments. Any documentation, such as validation reports then helps with compliance and later regulatory submissions and requests.
European Pharmaceutical Review
APRIL 10, 2025
billion Global concerns surrounding PFAS, or per- and polyfluoroalkyl substances, are due to their well-documented effects on human health and the environment. However, given that PFAS are ubiquitous in the environment from stain-resistant carpets and non-stick pans, to packaging and electronics, to name a few the task is not that simple.
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
FDA Law Blog: Biosimilars
JULY 10, 2023
Performance Metric FY 2018 FY 2019 FY 2020 FY 2021 FY 2022 Average Number of FDA Days to MDUFA IV Decision 72.62 In this case, the FDA clock start date is determined as the date of receiving the submission by the Document Control Center (DCC). Attachment number) and document name or description as appropriate.
GMPSOP
JUNE 28, 2024
Additional documents included each month. In the five years between 2019 and 2023, the FDA issued the following warning letters, closely related to ineffective deviation investigation. Packaging/labeling/Misbranding: 41 warnings vi. Additional documents included each month. All written and updated by GMP experts.
Pharmaceutical Technology
MARCH 30, 2023
There, the FDA suggested that the drugs undergo randomised controlled trials, which the document describes as the preferred approach, rather than single-arm trials. While the drug was granted accelerated approval in June 2019, it did not deliver on a key overall survival (OS) endpoint as part of its post-marketing data package.
National Association of Boards of Pharmacy
NOVEMBER 6, 2024
Launched in 2019, NABP’s Specialty Pharmacy Accreditation was created to accredit pharmacies providing advanced levels of pharmacy services and disease management tools for patients taking medications that require special handling, storage, and dispensing requirements.
The Nontraditional Pharmacist
JULY 1, 2025
So, we would have spoken in 2019. And then how do you develop documents to basically get approval from the FDA to study your drug in humans? Sometimes we exclude medications from our protocol, various CYP enzymes and kind of going through a package insert to see, should we exclude this drug or not? So, good talking to you.
Expert insights. Personalized for you.
52 
Let's personalize your content